News >

Expert Discusses Next Steps for Durvalumab in Bladder Cancer

Danielle Bucco
Published: Wednesday, Aug 23, 2017

Peter Black, MD

Peter Black, MD
Durvalumab (Imfinzi) was approved by the FDA in May 2017 for patients with locally advanced or metastatic urothelial carcinoma who received platinum-containing chemotherapy and have disease progression.  

, Peter Black, MD, a senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

OncLive: Can you discuss ongoing combination trials with durvalumab?

Black: We know that durvalumab works as a monotherapy in the second-line setting after cisplatin failure. The first trial that we completed in the first-line for cisplatin is a combination trial of durvalumab versus durvalumab plus tremelimumab versus standard chemotherapy. Everyone is excited and anxious to see the results of that trial.    
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication